Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVADEX for chronic Graft-versus-Host Disease
NCT00054613Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jun 2002
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, single-blind trial of methoxsalen in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Response rate in skin manifestations of chronic GvHD. Started Jun 2002; status: completed.
02
Drugs
methoxsalen
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT00054613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054613.